Stephanie Lovell's most recent trade in Transmedics Group Inc was a trade of 1,154 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on May 23, 2024.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Transmedics Group Inc | Stephanie Lovell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 1,154 | 1,154 | - | - | Stock Option (Right to Buy) | |
Transmedics Group Inc | Stephanie Lovell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 732 | 1,925 (0%) | 0% | 0 | Common Stock | |
Transmedics Group Inc | Stephanie Lovell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 1,916 | 1,916 | - | - | Stock Option (Right to Buy) | |
Transmedics Group Inc | Stephanie Lovell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 1,193 | 1,193 (0%) | 0% | 0 | Common Stock | |
Transmedics Group Inc | Stephanie Lovell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Nov 2022 | 5,657 | 8,543 | - | - | Stock Option (Right to Buy) | |
Transmedics Group Inc | Stephanie Lovell | Director | Sale of securities on an exchange or to another person at price $ 59.50 per share. | 22 Nov 2022 | 5,657 | 0 (0%) | 0% | 59.5 | 336,592 | Common Stock |
Transmedics Group Inc | Stephanie Lovell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 47.82 per share. | 22 Nov 2022 | 5,657 | 5,657 (0%) | 0% | 47.8 | 270,518 | Common Stock |
Transmedics Group Inc | Stephanie Lovell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 47.82 per share. | 22 Nov 2022 | 3,800 | 3,800 (0%) | 0% | 47.8 | 181,716 | Common Stock |
Transmedics Group Inc | Stephanie Lovell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Nov 2022 | 3,800 | 14,200 | - | - | Stock Option (Right to Buy) | |
Transmedics Group Inc | Stephanie Lovell | Director | Sale of securities on an exchange or to another person at price $ 57.97 per share. | 22 Nov 2022 | 3,800 | 0 (0%) | 0% | 58.0 | 220,286 | Common Stock |
Transmedics Group Inc | Stephanie Lovell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Nov 2022 | 1,100 | 1,150 | - | - | Stock Option (Right to Buy) | |
Transmedics Group Inc | Stephanie Lovell | Director | Sale of securities on an exchange or to another person at price $ 58.04 per share. | 22 Nov 2022 | 1,100 | 0 (0%) | 0% | 58.0 | 63,844 | Common Stock |
Transmedics Group Inc | Stephanie Lovell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.26 per share. | 22 Nov 2022 | 1,100 | 1,100 (0%) | 0% | 26.3 | 28,886 | Common Stock |
Cyclerion Therapeutics Inc | Stephanie Lovell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2022 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
Transmedics Group Inc | Stephanie Lovell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 13,500 | 13,500 | - | - | Stock Option (Right to Buy) | |
Cyclerion Therapeutics Inc | Stephanie Lovell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2021 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
Transmedics Group Inc | Stephanie Lovell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2021 | 2,250 | 2,250 | - | - | Stock Option (Right to Buy) | |
Transmedics Group Inc | Stephanie Lovell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Mar 2021 | 18,000 | 18,000 | - | - | Stock Option (Right to Buy) | |
Cyclerion Therapeutics Inc | Stephanie Lovell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2020 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) |